10-Q: Inspire Medical Systems Reports Q1 2025 Results: Revenue Up 22.7%, Company Achieves Net Income

Inspire Medical Systems reports a 22.7% increase in revenue for Q1 2025, reaching $201.3 million, and achieves net income of $3.0 million.

Summary

• Inspire Medical Systems, Inc. reported its financial results for the first quarter of 2025.
• Revenue increased by 22.7% to $201.3 million, compared to $164.0 million in Q1 2024.
• The company achieved a net income of $3.0 million, a significant improvement from the net loss of $10.0 million in the same period last year.
• Gross margin remained strong at 84.7%, slightly lower than the 84.9% reported in Q1 2024.
• Research and development expenses decreased slightly to $27.8 million.
• Selling, general, and administrative expenses increased to $144.3 million.
• The company repurchased shares worth $75.0 million under its share repurchase program.
• As of March 31, 2025, cash, cash equivalents, and available-for-sale debt securities totaled $414.0 million.
• The company is launching its next generation Inspire system ('Inspire V') in the U.S. in 2025.
• Some patients and physicians are delaying Inspire therapy until Inspire V is available, and some customers are using existing Inspire IV inventory before purchasing Inspire V systems, which may impact revenue in the short term.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and a return to profitability. However, there are some concerns about the short-term impact of the Inspire V launch and increasing expenses, which temper the overall sentiment.

Positives

• Significant revenue growth of 22.7% year-over-year.
• Return to profitability with a net income of $3.0 million.
• Strong gross margin maintained at 84.7%.
• Successful share repurchase program executed.
• Healthy cash position with $414.0 million in cash, cash equivalents, and available-for-sale debt securities.
• FDA approval and upcoming launch of next-generation Inspire V system.

Negatives

• Slight decrease in gross margin compared to Q1 2024 (84.7% vs 84.9%).
• Increase in selling, general, and administrative expenses to $144.3 million.
• Potential short-term impact on revenue due to patients and physicians delaying therapy for Inspire V and customers using existing Inspire IV inventory.

Risks

• Potential short-term impact on revenue due to the transition to Inspire V.
• Dependence on third-party suppliers for manufacturing the Inspire system.
• Competition from pharmaceutical treatments like GLP-1s for sleep apnea.
• Macroeconomic conditions could cause customers to decrease or delay orders.
• The company is involved in claims and litigation in the ordinary course of business, some of which seek monetary damages, including claims for punitive damages, which may not be covered by insurance.
• The company received a civil investigative demand (CID) from the Department of Justice U.S. Attorneys Office for the District of Minnesota pursuant to the False Claims Act in the course of the governments investigation concerning allegations of false claims, including false claims arising from violations of the Anti-Kickback Statute, submitted to government payors in connection with our implant.

Future Outlook

The company anticipates that the occurrence of patients and physicians delaying Inspire therapy until Inspire V is available and the destocking by some of our customers of their existing Inspire IV inventory may impact our consolidated revenue until Inspire V is fully launched and our customers have used their existing Inspire IV inventory, which is expected to primarily occur in the second quarter of 2025.

Management Comments

• The company is launching its next generation Inspire system ('Inspire V') in the U.S. in 2025.
• The company plans to continue to make Inspire IV systems available in the U.S. after the Inspire V launch as inventory levels allow, and outside the U.S., subject to our receiving the appropriate regulatory clearances for Inspire V in foreign markets.
• The company expects its direct-to-consumer expenditures to increase slightly over 2024 levels during the remainder of 2025.
• The company intends to continue to enhance and expand its scheduling capability during the remainder of 2025.

Industry Context

The report discusses the potential impact of GLP-1 drugs on the treatment of OSA and how Inspire therapy may complement these treatments. It also mentions the company's efforts to expand market penetration and increase physician and patient awareness of its Inspire system.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• It focuses on the company's performance and internal metrics rather than benchmarking against external entities.
• The document mentions Eli Lilly and Company and their SURMOUNT-OSA trial, but does not provide a direct comparison of Inspire's results to Lilly's results.

Legal Proceedings

• A securities class action lawsuit, City of Hollywood Firefighters Pension Fund v. Inspire Medical Systems, Inc., et. al., was dismissed with prejudice.
• A stockholder derivative lawsuit, Lawrence Hollin v. Herbert, et al., is pending a motion for voluntary dismissal.
• The company received a civil investigative demand (CID) from the Department of Justice U.S. Attorneys Office for the District of Minnesota pursuant to the False Claims Act in the course of the governments investigation concerning allegations of false claims, including false claims arising from violations of the Anti-Kickback Statute, submitted to government payors in connection with our implant.

Related Party Transactions

• The company shares the costs of a corporate suite at a sports and entertainment venue with an entity controlled by the Chief Executive Officer.

Stakeholder Impact

• Shareholders: Positive impact due to revenue growth, profitability, and share repurchase program.
• Employees: Potential for increased opportunities due to company growth and expansion.
• Customers: Access to new and improved Inspire V system.
• Suppliers: Continued business relationship with the company.
• Patients: Access to innovative solutions for obstructive sleep apnea.

Next Steps

• Fully launch the Inspire V system in the U.S. in 2025.
• Continue to make Inspire IV systems available as inventory allows.
• Expand digital advertising efforts to reach more qualified patients.
• Enhance and expand the digital scheduling program.
• Continue to expand clinical studies to further expand positive coverage policies from private commercial payors in the U.S. and enter into new markets including additional European countries and the Asia Pacific region.

Key Dates

Keywords

Inspire Medical Systems, obstructive sleep apnea, Inspire therapy, revenue, net income, gross margin, share repurchase, Inspire V, GLP-1s, financial results